This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Resources
Treatment Guidelines
| Guidelines | Link to guidelines |
|---|---|
|
NCCN (V5.2022) |
|
|
ESMO Clinical Practice Guidelines (2020) |
FDA approved drugs for NHL
| Generic name | Trade name | Link to prescribing information |
|---|---|---|
|
Acalabrutinib |
Calquence® |
|
|
Axicabtagene siloleucel |
Yescarta® |
|
|
Bendamustine |
Bendeka® |
|
|
Brentuximab vedotin |
Adcetris® |
|
|
Brexucabtagene autoleucel |
Tecartus® |
|
|
Copanlisib |
Aliqopa® |
|
|
Cyclophosphamide |
Generic |
|
|
Doxorubicin |
Generic |
|
|
Fludarabine |
Generic |
|
|
Ibritumomab tiuxetan |
Zevalin® |
|
|
Ibrutinib |
Imbruvica® |
|
|
Lenalidomide |
Revlimid® |
|
|
Lisocabtagene caraleucel |
Breyanzi® |
|
|
Loncastuximab tesirine-lpyl |
Zynlonta® |
|
|
Ofatumumab |
Arzerra® |
|
|
Obinutuzumab |
Gazyva® |
|
|
Pembrolizumab |
Keytruda® |
|
|
Polatuzumab vedotin-piiq |
Polivy® |
|
|
Prednisone |
Generic |
|
|
Rituximab |
Rituxan® |
|
|
Selinexor |
Xpovio® |
|
|
Tafasitamab-cxix |
Monjuvi® |
|
|
Tazemetostat |
Tazverik® |
|
|
Tisagenlecleucel |
Kymriah® |
|
|
Ventoclax |
Venclexta® |
|
|
Vincristine |
Vincasar® |
|
|
Zanubrutinib |
Brukinsa® |
Ongoing clinical trials and new therapeutics for DLBCL1
| Agent | Agent type | Combined agent | Study |
|---|---|---|---|
| Odronextamab | CD20 x CD3 | bispecific antibody | NCT03888105 |
| Odronextamab | CD20 x CD3 | bispecific antibody | NCT02290951 |
| Odronextamab | CD20 x CD3 | bispecific antibody | NCT05619367 |
| Idelalisib | PI3K inhibitor | - | NCT03576443 |
| Copanlisib | PI3Kα/δ inhibitor | Nivolumab | NCT03484819 |
| Parsaclisib | PI3Kδ inhibitor | - | NCT02998476 |
| Parsaclisib | PI3Kδ inhibitor | R-CHOP | NCT04323956 |
| Parsaclisib | PI3Kδ inhibitor | Rituximab, bendamustine/ibrutinib | NCT03424122 |
| BR101801 | PI3Kδ and DNA-PK dual inhibitor | - | NCT04018248 |
| Umbralisib (TGR-1202) | PI3Kδ and CK1 dual inhibitor | Ublituximab, bendamustine | NCT02793583 |
| Everolimus | mTORC1 inhibitor | Lenalidomide | NCT01075321 |
| Temsirolimus | mTORC1 inhibitor | Rituximab, DHAP | NCT01653067 |
| Venetoclax | BCL2 inhibitor | - | NCT01328626 |
| Venetoclax | BCL2 inhibitor | Lenalidomide, obinutuzumab | NCT02992522 |
| Venetoclax | BCL2 inhibitor | Atezolizumab, obinutuzumab | NCT03276468 |
| Venetoclax | BCL2 inhibitor | RICE | NCT03064867 |
| Venetoclax | BCL2 inhibitor | DA-EPOCH-R | NCT03036904 |
| Venetoclax | BCL2 inhibitor | DA-EPOCH-R | NCT02611323 |
| Venetoclax | BCL2 inhibitor | Obinutuzumab | NCT02987400 |
| Entospletinib | Spleen tyrosine kinase inhibitor | R-CHOP | NCT03225924 |
| Ibrutinib | BTK inhibitor | ABT-199, rituximab | NCT03136497 |
| Ibrutinib | BTK inhibitor | ABT-199, prednisone, obinutuzumab, lenalidomide | NCT03223610 |
| Ibrutinib | BTK inhibitor | Loncastuximab tesirine | NCT03684694 |
| Ibrutinib | BTK inhibitor | Lenalidomide, rituximab | NCT02077166 |
| Ibrutinib | BTK inhibitor | R-ICE | NCT02955628 |
| Ibrutinib | BTK inhibitor | Buparlisib | NCT02756247 |
| ARQ-531 | BTK inhibitor | - | NCT03162536 |
| LOXO-305 | BTK inhibitor | Venetoclax, R-CHOP | NCT03740529 |
| DTRMWXHS-12 | BTK inhibitor | Everolimus, pomalidomide | NCT04305444 |
| Acalabrutinib | BTK inhibitor | - | NCT02112526 |
| Acalabrutinib | BTK inhibitor | RICE | NCT03736616 |
| Acalabrutinib | BTK inhibitor | DA-EPOCH | NCT04002947 |
| Acalabrutinib | BTK inhibitor | R-CHOP | NCT03571308 |
| Acalabrutinib | BTK inhibitor | pembrolizumab | NCT02362035 |
| Enzastaurin | PKCβ inhibitor | R-CHOP | NCT03263026 |
| Lenalidomide | Immunomodulatory agent | - | NCT04150328 |
| Lenalidomide | Immunomodulatory agent | MOR208 | NCT02399085 |
| Lenalidomide | Immunomodulatory agent | R-CHOP | NCT00670358 |
| Lenalidomide | Immunomodulatory agent | R-CHOP | NCT00907348 |
| Lenalidomide | Immunomodulatory agent | R-CHOP | NCT01856192 |
| Lenalidomide | Immunomodulatory agent | R-CHOP | NCT02285062 |
| Lenalidomide | Immunomodulatory agent | miniCHOP, subcutaneous rituximab | NCT02128061 |
| Lenalidomide | Immunomodulatory agent | Rituximab, ibrutinib | NCT02636322 |
| Itacitinib | JAK1 inhibitor | Parsaclisib | NCT02018861 |
| Itacitinib | JAK1 inhibitor | Ibrutinib | NCT02760485 |
| Ruxolitinib | JAK1/2 inhibitor | - | NCT01431209 |
| Valemetostat | EZH1/2 dual inhibitor | - | NCT02732275 |
| Tazemetostat | EZH2 inhibitor | - | NCT01897571 |
| Tazemetostat | EZH2 inhibitor | R-CHOP | NCT02889523 |
| Tazemetostat | EZH2 inhibitor | - | NCT03456726 |
| Tazemetostat | EZH2 inhibitor | - | NCT02875548 |
| Panobinostat | HDACi | - | NCT01261247 |
| Vorinostat | HDACi | R-CHOP | NCT00972478 |
| Chidamide | HDACi | - | NCT03201471 |
| Romidepsin | HDACi | 5-Azacitidine | NCT01998035 |
| Selinexor | XPO1 inhibitor | Venetoclax | NCT03955783 |
| Selinexor | XPO1 inhibitor | R-CHOP | NCT03147885 |
| Selinexor | XPO1 inhibitor | RICE | NCT02471911 |
Ongoing clinical trials and new therapeutics for FL
| Agent | Agent type | Combined agent | Study |
|---|---|---|---|
| Epcoritamab | CD20 x CD3 bispecific antibody | NCT03625037 | |
| Glofitamab | CD20 x CD3 bispecific antibody | Obinutuzumab | NCT03075696 |
| Mosunetuzumab | CD20 x CD3 bispecific antibody | Atezolizumab | NCT02500407 |
| Mosunetuzumab | CD20 x CD3 bispecific antibody | Lenalidomide | NCT04246086 |
| Odronextamab | CD20 x CD3 bispecific antibody | NCT02290951 |
Websites
| Resource | Address |
|---|---|
|
American Cancer Society (ACS). What Is Non-Hodgkin's Lymphoma? |
|
|
ASCO Cancer.Net. Lymphoma - Non-Hodgkin's. |
|
|
Leukemia & Lymphoma Society. Non-Hodgkin's Lymphoma. |
|
|
Lymphoma Research Foundation. Non-Hodgkin's Lymphoma. |
|
|
Mayo Clinic. Non-Hodgkin's Lymphoma. |
|
|
MedlinePlus. Non-Hodgkin's Lymphoma. |
|
|
National Cancer Institute. Adult Non-Hodgkin's Lymphoma Treatment (PDQ®)–Health Professional Version. Updated August 31, 2022. |
|
|
National Comprehensive Cancer Network (NCCN) |
|
|
US National Library of Medicine. Clinical Trials |
All URLs accessed on September 25, 2022.
Bispecific Antibodies under investigation in FL2
References
- Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13:175. https://doi.org/10.1186/s13045-020-01011-z
